What is Varicose veins treatment Market?
The varicose veins treatment market is expected to grow in the future due to the increasing adoption of advanced treatment procedures and favorable government initiatives. Varicose veins are large, swollen veins that often appear on the legs and feet. They happen when the valves in the veins do not work properly, so the blood does not flow effectively. Furthermore, an increasing number of ABVLM-certified physicians will boost the demand for minimally invasive laser therapy to treat varicose veins.
The market study is being classified and major geographies with country level break-up.
Medtronic plc (Ireland), AngioDynamics, Inc. (United States), biolitec AG (Austria), Syneron Medical Ltd. (Israel), Lumenis Ltd. (Israel), Dornier MedTech GmbH (Germany), Energist Group (United Kingdom), Eufoton s.r.l. (Italy), Vascular Solutions, Inc. (United States) and Quanta System S.p.A. (Italy) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sciton, Inc. (United States), Fotona d.o.o. (Slovenia), BTG plc (United Kingdom) and Merz Aesthetics (United States).
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Varicose veins treatment market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Varicose veins treatment market by Type, Application and Region.
On the basis of geography, the market of Varicose veins treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Rising Incidence and Prevalence of Varicose Veins Worldwide
- Increasing Geriatric Population
Market Trend
- Technological Advancement in the Varicose Veins Treatment Device
Restraints
Opportunities
- Increasing Number of ABVLM-certified Physicians
- Availability of Advanced Healthcare Infrastructure in Developing Countries
Challenges
- Risk Factors associated with the Treatment Devices
Market Leaders and some development strategies
In Aug 2019, Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.
In June 2020, Medtronic plc announced the first-ever results from the ABRE clinical study assessing the safety and effectiveness of the investigational Abre™ venous self-expanding stent system in subjects with iliofemoral venous outflow obstruction. The study met the primary safety and effectiveness endpoints.
In February 2015, the Food and Drug Administration (FDA) reviewed data for the premarket approval of the VenaSeal system. The FDA approval for the VenaSeal system included from the analysis of results from three clinical studies. Medtronic announced that new CPT codes may aid in getting positive coverage for its VenaSeal closure device from the public and private insurers in the United States in November 2017.
Key Target Audience
Varicose vein treatment Provider, Treatment Product Manufacturers, Vendors, and Distributors, Research Institutes, Government Organizations, Venture capitalists and other government funding organizations, Research and Consulting Firms, Healthcare Industry, Pharmaceutical Companies and Biotechnology Companies